About
Activity
-
Simultaneously hard to believe it has been just a month AND already a month since I joined VantAI team. - Day 1 - start in Zurich office - Day 2 -…
Simultaneously hard to believe it has been just a month AND already a month since I joined VantAI team. - Day 1 - start in Zurich office - Day 2 -…
Liked by Evan Feinberg
-
Today was my last day working at BMS. I am so very grateful for all the friends, mentors, wonderful collaborators and cutting edge science that the…
Today was my last day working at BMS. I am so very grateful for all the friends, mentors, wonderful collaborators and cutting edge science that the…
Liked by Evan Feinberg
-
After 7 incredible years at 3T, I've made the decision to transition into an advisory role and step away from my operating role. It's been an…
After 7 incredible years at 3T, I've made the decision to transition into an advisory role and step away from my operating role. It's been an…
Liked by Evan Feinberg
Experience & Education
-
Genesis Therapeutics
View Evan’s full experience
See their title, tenure and more.
or
Publications
-
Structural insights into µ-opioid receptor activation
Nature
See publicationFrom the abstract, "Activation of the μ-opioid receptor (μOR) is responsible for the efficacy of the most effective analgesics. To shed light on the structural basis for μOR activation, here we report a 2.1 Å X-ray crystal structure of the murine μOR bound to the morphinan agonist BU72 and a G protein mimetic camelid antibody fragment. The BU72-stabilized changes in the μOR binding pocket are subtle and differ from those observed for agonist-bound structures of the β2-adrenergic receptor (β2AR)…
From the abstract, "Activation of the μ-opioid receptor (μOR) is responsible for the efficacy of the most effective analgesics. To shed light on the structural basis for μOR activation, here we report a 2.1 Å X-ray crystal structure of the murine μOR bound to the morphinan agonist BU72 and a G protein mimetic camelid antibody fragment. The BU72-stabilized changes in the μOR binding pocket are subtle and differ from those observed for agonist-bound structures of the β2-adrenergic receptor (β2AR) and the M2 muscarinic receptor. Comparison with active β2AR reveals a common rearrangement in the packing of three conserved amino acids in the core of the μOR, and molecular dynamics simulations illustrate how the ligand-binding pocket is conformationally linked to this conserved triad. Additionally, an extensive polar network between the ligand-binding pocket and the cytoplasmic domains appears to play a similar role in signal propagation for all three G-protein-coupled receptors."
-
Structural basis for chemokine recognition and activation of a viral G protein–coupled receptor
Science
From the absract, "Chemokines are small proteins that function as immune modulators through activation of chemokine G protein–coupled receptors (GPCRs). Several viruses also encode chemokines and chemokine receptors to subvert the host immune response. How protein ligands activate GPCRs remains unknown. We report the crystal structure at 2.9 angstrom resolution of the human cytomegalovirus GPCR US28 in complex with the chemokine domain of human CX3CL1 (fractalkine). The globular body of CX3CL1…
From the absract, "Chemokines are small proteins that function as immune modulators through activation of chemokine G protein–coupled receptors (GPCRs). Several viruses also encode chemokines and chemokine receptors to subvert the host immune response. How protein ligands activate GPCRs remains unknown. We report the crystal structure at 2.9 angstrom resolution of the human cytomegalovirus GPCR US28 in complex with the chemokine domain of human CX3CL1 (fractalkine). The globular body of CX3CL1 is perched on top of the US28 extracellular vestibule, whereas its amino terminus projects into the central core of US28. The transmembrane helices of US28 adopt an active-state–like conformation. Atomic-level simulations suggest that the agonist-independent activity of US28 may be due to an amino acid network evolved in the viral GPCR to destabilize the receptor’s inactive state."
Other authors -
-
Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes
International Journal of Nanomedicine
Patents
-
Method of Recommending Nodes of a Network using a Self-Improving Graph Data Structure
Filed US 61/793,289
Other inventors -
-
Ligands of the Mu, Kappa, and Delta Opioid Receptors
US 62/585,796
Other inventors -
-
Machine Learning and Molecular Simulation Based Methods for Enhancing Binding and Activity Prediction
US 62/638,805
Other inventors -
-
Spatial Graph Convolutions with Applications to Drug Discovery
US 62/638,803
Other inventors -
Honors & Awards
-
Forbes 30 under 30
-
https://www.forbes.com/30-under-30/2020/healthcare/
-
Blue Waters Graduate Fellowship
National Center for Supercomputing Applications
Full funding for graduate school and extensive time on the Blue Waters supercomputer.
-
The Applied Physics Prize
Yale University
-
Phi Beta Kappa
-
More activity by Evan
-
Special thanks to our outstanding team of AI experts and drug hunters for making this possible, and to Max Bayer for a great conversation about…
Special thanks to our outstanding team of AI experts and drug hunters for making this possible, and to Max Bayer for a great conversation about…
Shared by Evan Feinberg
-
Enjoyed sitting down with John Carroll and an engaging group of panelists at the #WuxiGlobalForum this week at JPM. Thanks WuXi AppTec for the…
Enjoyed sitting down with John Carroll and an engaging group of panelists at the #WuxiGlobalForum this week at JPM. Thanks WuXi AppTec for the…
Shared by Evan Feinberg
-
I'm thrilled and honored to be starting 2024 as a partner at Munger, Tolles & Olson LLP! It is a true pleasure and privilege to practice with my…
I'm thrilled and honored to be starting 2024 as a partner at Munger, Tolles & Olson LLP! It is a true pleasure and privilege to practice with my…
Liked by Evan Feinberg
-
Looking forward to #MoML2023 @ MIT tomorrow! Come say hi 👋, find out what our team's been up to 🤓, and learn about opportunities at Genesis! 🚀
Looking forward to #MoML2023 @ MIT tomorrow! Come say hi 👋, find out what our team's been up to 🤓, and learn about opportunities at Genesis! 🚀
Liked by Evan Feinberg
-
I had the opportunity to sit down with Vijay Pande, PhD – friend, former Ph.D. adviser, and our latest lead investor with @a16z – for an episode of…
I had the opportunity to sit down with Vijay Pande, PhD – friend, former Ph.D. adviser, and our latest lead investor with @a16z – for an episode of…
Shared by Evan Feinberg
Other similar profiles
-
Vijay Pande, PhD
Connect -
Ben Sklaroff
Connect -
Carl Tilbury
Connect -
Stephen Dann
Connect -
Marissa (Smith) Baker
Connect -
Matteus Pan
Connect -
Vyom Thakkar
Connect -
Wojtek Swiderski
Connect -
Vincent Liu
PhD Candidate at Stanford University
Connect -
Christina Adams
Associate Director, Biology at Genesis Therapeutics
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Evan Feinberg in United States
-
Evan Feinberg
Senior Vice President at Stand Together and Chairman of Stand Together Foundation.
-
Evan Feinberg
-
Evan Feinberg
Emergency Medicine Physician
-
Evan Feinberg
Founder and CEO at Genesis Therapeutics
9 others named Evan Feinberg in United States are on LinkedIn
See others named Evan Feinberg